GlassScriptPhysician profile
Archana Vasudevan
NPI 1194130088
$1,391.85
in general payments reported to CMS, 2019-2025
18 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $224 · 2021: $207 · 2022: $124 · 2023: $155 · 2024: $293 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.15 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $189.88 | 2021-2025 | Veklury, Epclusa |
| Insmed, INC. | $188.14 | 2020-2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $167.94 | 2019-2025 | Vibativ |
| Astellas Pharma US INC | $156.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $120.13 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $98.13 | 2022-2025 | Nuzyra |
| Abbvie INC. | $89.64 | 2021-2022 | |
| Misonix INC | $69.55 | 2019 | |
| Shionogi INC | $66.29 | 2021-2024 | Fetroja |
| Smith+Nephew, INC. | $55.32 | 2019-2023 | Collagenase Santyl, Regranex |
| Organogenesis INC. | $52.64 | 2022 | |
| Aimmune Therapeutics, INC. | $40.00 | 2023-2024 | |
| Urgo Medical North America, LLC | $25.12 | 2025 | Urgoclean Ag |
| Ferring Pharmaceuticals INC. | $17.59 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $15.56 | 2020 | |
| Allergan, INC. | $12.10 | 2020 | |
| Molnlycke Health Care US, LLC | $10.88 | 2023 | Mepitel One, Exufiber Ag+, Mepilex Border Flex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Vasudevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.